Glycine

The most common entry point for glycine supplementation is the sleep protocol: 3 grams dissolved in water about 30 to 60 minutes before bed. Most people notice the effects within the first few nights. Sleep onset tends to feel smoother and faster, without the heaviness or grogginess associated with sedative sleep aids like melatonin or diphenhydramine. The deeper change shows up the next morning -- people consistently report waking up feeling more refreshed, with noticeably less of that sluggish, sleep-inertia fog. The powder itself is mildly sweet (glycine literally means "sweet"), which makes it one of the more pleasant supplements to take plain in water.

During the day, higher doses in the 5 to 10 gram range can produce a subtle calming effect without sedation. It is not anxiolytic in the way that something like L-theanine or phenibut is -- there is no distinct "wave" of relaxation. Instead, people describe a gentle background quieting, a slight reduction in mental noise. For the GlyNAC protocol (typically 1.2 grams glycine plus 600 milligrams NAC, twice daily), the effects are not immediate. Users report improvements in energy, skin quality, and general vitality building gradually over 4 to 8 weeks, consistent with the timeline for glutathione repletion. Community feedback on glycine for sleep is overwhelmingly positive -- it ranks among the most reliably effective and well-tolerated sleep supplements discussed on forums like r/Supplements and r/Nootropics.

Glycine activates strychnine-sensitive glycine receptors (GlyRs), ligand-gated chloride channels that mediate inhibitory neurotransmission in the spinal cord, brainstem, and retina. GlyRs are pentameric channels composed of alpha and beta subunits. Glycine-mediated inhibition is essential for motor coordination, pain processing, and respiratory rhythm generation.

At NMDA receptors, glycine is a mandatory co-agonist. NMDA receptor activation requires simultaneous binding of glutamate at the GluN2 subunit and glycine (or D-serine) at the GluN1 subunit, plus membrane depolarization to relieve the Mg2+ block. The glycine site is not normally fully saturated in vivo, meaning increasing glycine availability can enhance NMDA receptor function. This is the basis for glycine's therapeutic use in schizophrenia (where NMDA hypofunction is hypothesized).

Glycine also serves as a precursor for glutathione (the tripeptide Glu-Cys-Gly, the body's primary intracellular antioxidant), creatine (from glycine + arginine + methionine), heme (from glycine + succinyl-CoA), purines (DNA/RNA building blocks), and collagen (glycine constitutes every third amino acid). Glycine taken before bedtime improves sleep quality by reducing core body temperature through peripheral vasodilation and by modulating NMDA receptors in the suprachiasmatic nucleus.

Glycine was first isolated from gelatin (a collagen derivative) in 1820 by Henri Braconnot through acid hydrolysis. The name derives from the Greek glykys (sweet), referring to its sweet taste. Glycine was confirmed as an inhibitory neurotransmitter in the spinal cord by Aprison and Werman in 1965, and strychnine was identified as its receptor antagonist (explaining strychnine's lethal convulsant effects).

The discovery of the glycine co-agonist site on NMDA receptors by Johnson and Ascher in 1987 revealed glycine's excitatory role and transformed understanding of glutamatergic neurotransmission. This led to clinical trials of glycine as an adjunctive treatment for schizophrenia, based on the glutamate/NMDA hypofunction hypothesis.

The sleep-promoting effects of glycine were demonstrated in a series of studies by Bannai and colleagues at Ajinomoto (the MSG manufacturer), published in 2006-2012, showing that 3 g glycine before bedtime improved subjective sleep quality, reduced sleep onset latency, and improved next-day cognitive performance.